Evolocumab (Evol), a proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitor, has attracted widespread attention in atherosclerosis therapy due to its function of lowering LDL-C [6]. However, how to reduce the dosage and enhance the targeting without affecting the efficacy is the key problem of using this drug in the treatment of atherosclerosis. This evidence concerns the gene PCSK9 and atherosclerosis.